Annual CFO
-$4.34 M
+$14.99 M+77.54%
December 31, 2023
Summary
- As of March 10, 2025, FRTX annual cash flow from operations is -$4.34 million, with the most recent change of +$14.99 million (+77.54%) on December 31, 2023.
- During the last 3 years, FRTX annual CFO has risen by +$15.69 million (+78.32%).
- FRTX annual CFO is now -720.43% below its all-time high of $700.00 thousand, reached on December 1, 1992.
Performance
FRTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$1.12 M
-$4.21 M-136.47%
December 31, 2023
Summary
- As of March 10, 2025, FRTX quarterly cash flow from operations is -$1.12 million, with the most recent change of -$4.21 million (-136.47%) on December 31, 2023.
- Over the past year, FRTX quarterly CFO has stayed the same.
- FRTX quarterly CFO is now -107.05% below its all-time high of $15.94 million, reached on September 1, 2011.
Performance
FRTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$4.34 M
+$1.45 M+25.08%
December 31, 2023
Summary
- As of March 10, 2025, FRTX TTM cash flow from operations is -$4.34 million, with the most recent change of +$1.45 million (+25.08%) on December 31, 2023.
- Over the past year, FRTX TTM CFO has stayed the same.
- FRTX TTM CFO is now -199.86% below its all-time high of $4.35 million, reached on June 1, 2012.
Performance
FRTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
FRTX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +77.5% | 0.0% | 0.0% |
| 3 y3 years | +78.3% | 0.0% | 0.0% |
| 5 y5 years | +69.9% | 0.0% | 0.0% |
FRTX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +88.0% | -136.5% | +88.2% | at high | +89.1% |
| 5 y | 5-year | at high | +88.0% | -136.5% | +92.2% | at high | +89.1% |
| alltime | all time | -720.4% | +88.0% | -107.0% | +92.2% | -199.9% | +89.1% |
Fresh Tracks Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$4.34 M(-77.5%) | -$1.12 M(-136.5%) | -$4.34 M(-25.1%) |
| Sep 2023 | - | $3.08 M(-269.7%) | -$5.80 M(-55.8%) |
| Jun 2023 | - | -$1.82 M(-59.5%) | -$13.13 M(-8.1%) |
| Mar 2023 | - | -$4.49 M(+74.0%) | -$14.28 M(-26.1%) |
| Dec 2022 | -$19.34 M(-46.5%) | -$2.58 M(-39.3%) | -$19.34 M(-10.3%) |
| Sep 2022 | - | -$4.25 M(+43.1%) | -$21.55 M(-24.2%) |
| Jun 2022 | - | -$2.97 M(-68.9%) | -$28.45 M(-28.5%) |
| Mar 2022 | - | -$9.54 M(+98.8%) | -$39.80 M(+10.1%) |
| Dec 2021 | -$36.15 M(+80.4%) | - | - |
| Dec 2021 | - | -$4.80 M(-56.9%) | -$36.15 M(+0.1%) |
| Sep 2021 | - | -$11.14 M(-22.1%) | -$36.10 M(+24.7%) |
| Jun 2021 | - | -$14.31 M(+143.0%) | -$28.95 M(+49.9%) |
| Mar 2021 | - | -$5.89 M(+24.0%) | -$19.32 M(-3.6%) |
| Dec 2020 | -$20.03 M(-44.3%) | -$4.75 M(+19.0%) | -$20.03 M(-31.7%) |
| Sep 2020 | - | -$3.99 M(-14.7%) | -$29.32 M(-22.3%) |
| Jun 2020 | - | -$4.68 M(-29.2%) | -$37.76 M(+1.3%) |
| Mar 2020 | - | -$6.61 M(-52.9%) | -$37.27 M(+3.6%) |
| Dec 2019 | -$35.98 M(+149.1%) | -$14.04 M(+12.9%) | -$35.98 M(+46.8%) |
| Sep 2019 | - | -$12.43 M(+196.6%) | -$24.52 M(+60.0%) |
| Jun 2019 | - | -$4.19 M(-21.1%) | -$15.32 M(+0.9%) |
| Mar 2019 | - | -$5.32 M(+106.2%) | -$15.19 M(+5.2%) |
| Dec 2018 | -$14.45 M(+67.9%) | -$2.58 M(-20.4%) | -$14.45 M(+6.5%) |
| Sep 2018 | - | -$3.24 M(-20.3%) | -$13.56 M(+2.3%) |
| Jun 2018 | - | -$4.06 M(-11.1%) | -$13.26 M(+16.5%) |
| Mar 2018 | - | -$4.57 M(+169.3%) | -$11.38 M(+32.3%) |
| Dec 2017 | -$8.60 M(+2.5%) | -$1.70 M(-42.2%) | -$8.60 M(-1.3%) |
| Sep 2017 | - | -$2.93 M(+34.1%) | -$8.71 M(-2.5%) |
| Jun 2017 | - | -$2.19 M(+22.5%) | -$8.94 M(+5.3%) |
| Mar 2017 | - | -$1.79 M(-1.3%) | -$8.49 M(+1.2%) |
| Dec 2016 | -$8.39 M(+20.7%) | -$1.81 M(-42.6%) | -$8.39 M(-0.1%) |
| Sep 2016 | - | -$3.16 M(+81.9%) | -$8.40 M(+65.3%) |
| Jun 2016 | - | -$1.74 M(+2.8%) | -$5.08 M(-12.2%) |
| Mar 2016 | - | -$1.69 M(-7.3%) | -$5.79 M(-16.7%) |
| Dec 2015 | -$6.95 M(-29.1%) | -$1.82 M(-1222.8%) | -$6.95 M(-10.5%) |
| Sep 2015 | - | $162.00 K(-106.6%) | -$7.76 M(-24.6%) |
| Jun 2015 | - | -$2.44 M(-14.3%) | -$10.30 M(+0.0%) |
| Mar 2015 | - | -$2.85 M(+8.3%) | -$10.29 M(+5.0%) |
| Dec 2014 | -$9.81 M(-67.1%) | -$2.63 M(+10.8%) | -$9.81 M(-22.2%) |
| Sep 2014 | - | -$2.38 M(-2.7%) | -$12.61 M(-33.1%) |
| Jun 2014 | - | -$2.44 M(+3.4%) | -$18.84 M(-21.1%) |
| Mar 2014 | - | -$2.36 M(-56.6%) | -$23.89 M(-19.8%) |
| Dec 2013 | -$29.80 M(+72.9%) | -$5.43 M(-36.9%) | -$29.80 M(-0.9%) |
| Sep 2013 | - | -$8.61 M(+15.0%) | -$30.08 M(+15.6%) |
| Jun 2013 | - | -$7.48 M(-9.5%) | -$26.01 M(+48.7%) |
| Mar 2013 | - | -$8.27 M(+44.8%) | -$17.49 M(+1.5%) |
| Dec 2012 | -$17.23 M(+373.5%) | -$5.71 M(+25.8%) | -$17.23 M(+6.8%) |
| Sep 2012 | - | -$4.54 M(-539.4%) | -$16.13 M(-470.9%) |
| Jun 2012 | - | $1.03 M(-112.9%) | $4.35 M(-248.0%) |
| Mar 2012 | - | -$8.01 M(+73.5%) | -$2.94 M(-19.3%) |
| Dec 2011 | -$3.64 M(-87.1%) | -$4.62 M(-129.0%) | -$3.64 M(-12.4%) |
| Sep 2011 | - | $15.94 M(-354.9%) | -$4.15 M(-84.1%) |
| Jun 2011 | - | -$6.25 M(-28.2%) | -$26.04 M(-4.0%) |
| Mar 2011 | - | -$8.71 M(+69.8%) | -$27.11 M(-3.9%) |
| Dec 2010 | -$28.23 M(+31.6%) | -$5.13 M(-13.8%) | -$28.23 M(-2.8%) |
| Sep 2010 | - | -$5.95 M(-18.8%) | -$29.03 M(+5.7%) |
| Jun 2010 | - | -$7.33 M(-25.4%) | -$27.47 M(+15.5%) |
| Mar 2010 | - | -$9.82 M(+65.5%) | -$23.78 M(+10.9%) |
| Dec 2009 | -$21.45 M(-30.5%) | -$5.93 M(+35.3%) | -$21.45 M(-2.0%) |
| Sep 2009 | - | -$4.39 M(+20.6%) | -$21.89 M(-14.3%) |
| Jun 2009 | - | -$3.64 M(-51.5%) | -$25.55 M(-8.8%) |
| Mar 2009 | - | -$7.49 M(+17.6%) | -$28.02 M(-9.2%) |
| Dec 2008 | -$30.87 M | -$6.37 M(-20.9%) | -$30.87 M(+5.4%) |
| Sep 2008 | - | -$8.05 M(+31.8%) | -$29.29 M(+16.6%) |
| Jun 2008 | - | -$6.11 M(-40.9%) | -$25.11 M(-4.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | -$10.34 M(+115.9%) | -$26.34 M(+8.9%) |
| Dec 2007 | -$24.18 M(+54.3%) | -$4.79 M(+23.4%) | -$24.18 M(-4.4%) |
| Sep 2007 | - | -$3.88 M(-47.1%) | -$25.30 M(+25.6%) |
| Jun 2007 | - | -$7.33 M(-10.4%) | -$20.14 M(+25.3%) |
| Mar 2007 | - | -$8.18 M(+38.5%) | -$16.08 M(+2.6%) |
| Dec 2006 | -$15.67 M(-31.2%) | -$5.91 M(-561.1%) | -$15.67 M(+2.1%) |
| Sep 2006 | - | $1.28 M(-139.2%) | -$15.35 M(-30.0%) |
| Jun 2006 | - | -$3.27 M(-57.9%) | -$21.93 M(+8.4%) |
| Mar 2006 | - | -$7.77 M(+39.0%) | -$20.23 M(-11.2%) |
| Dec 2005 | -$22.78 M(+8.1%) | -$5.59 M(+5.6%) | -$22.78 M(+5.1%) |
| Sep 2005 | - | -$5.29 M(+236.8%) | -$21.68 M(+11.1%) |
| Jun 2005 | - | -$1.57 M(-84.8%) | -$19.51 M(-18.5%) |
| Mar 2005 | - | -$10.32 M(+130.0%) | -$23.93 M(+13.6%) |
| Dec 2004 | -$21.07 M(-2.2%) | -$4.49 M(+43.7%) | -$21.07 M(-6.1%) |
| Sep 2004 | - | -$3.12 M(-48.0%) | -$22.43 M(-8.7%) |
| Jun 2004 | - | -$6.00 M(-19.5%) | -$24.56 M(+8.9%) |
| Mar 2004 | - | -$7.46 M(+27.5%) | -$22.54 M(+4.7%) |
| Dec 2003 | -$21.54 M(+12.9%) | -$5.85 M(+11.4%) | -$21.54 M(+1.7%) |
| Sep 2003 | - | -$5.25 M(+31.6%) | -$21.17 M(+6.2%) |
| Jun 2003 | - | -$3.99 M(-38.2%) | -$19.93 M(-0.2%) |
| Mar 2003 | - | -$6.45 M(+17.7%) | -$19.96 M(+4.6%) |
| Dec 2002 | -$19.08 M(+131.5%) | -$5.48 M(+36.7%) | -$19.08 M(+13.4%) |
| Sep 2002 | - | -$4.01 M(-0.4%) | -$16.82 M(+22.9%) |
| Jun 2002 | - | -$4.02 M(-27.7%) | -$13.68 M(+26.9%) |
| Mar 2002 | - | -$5.57 M(+72.9%) | -$10.78 M(+30.8%) |
| Dec 2001 | -$8.24 M(-4.4%) | -$3.22 M(+268.5%) | -$8.24 M(+9.5%) |
| Sep 2001 | - | -$873.90 K(-22.0%) | -$7.52 M(-2.6%) |
| Jun 2001 | - | -$1.12 M(-63.0%) | -$7.73 M(-9.8%) |
| Mar 2001 | - | -$3.03 M(+20.8%) | -$8.56 M(-0.6%) |
| Dec 2000 | -$8.62 M(+43.6%) | -$2.50 M(+132.9%) | -$8.62 M(+24.7%) |
| Sep 2000 | - | -$1.08 M(-45.1%) | -$6.91 M(-17.1%) |
| Jun 2000 | - | -$1.96 M(-36.3%) | -$8.34 M(+3.2%) |
| Mar 2000 | - | -$3.08 M(+284.7%) | -$8.08 M(+34.6%) |
| Dec 1999 | -$6.00 M(+11.1%) | -$800.00 K(-68.0%) | -$6.00 M(+5.3%) |
| Sep 1999 | - | -$2.50 M(+47.1%) | -$5.70 M(-3.4%) |
| Jun 1999 | - | -$1.70 M(+70.0%) | -$5.90 M(-1.7%) |
| Mar 1999 | - | -$1.00 M(+100.0%) | -$6.00 M(+11.1%) |
| Dec 1998 | -$5.40 M(+17.4%) | -$500.00 K(-81.5%) | -$5.40 M(-1.8%) |
| Sep 1998 | - | -$2.70 M(+50.0%) | -$5.50 M(+111.5%) |
| Jun 1998 | - | -$1.80 M(+350.0%) | -$2.60 M(+8.3%) |
| Mar 1998 | - | -$400.00 K(-33.3%) | -$2.40 M(-47.8%) |
| Dec 1997 | -$4.60 M(-6.1%) | -$600.00 K(-400.0%) | -$4.60 M(-24.6%) |
| Sep 1997 | - | $200.00 K(-112.5%) | -$6.10 M(-19.7%) |
| Jun 1997 | - | -$1.60 M(-38.5%) | -$7.60 M(+43.4%) |
| Mar 1997 | - | -$2.60 M(+23.8%) | -$5.30 M(+8.2%) |
| Dec 1996 | -$4.90 M(+48.5%) | -$2.10 M(+61.5%) | -$4.90 M(+81.5%) |
| Sep 1996 | - | -$1.30 M(-285.7%) | -$2.70 M(-15.6%) |
| Jun 1996 | - | $700.00 K(-131.8%) | -$3.20 M(-5.9%) |
| Mar 1996 | - | -$2.20 M(-2300.0%) | -$3.40 M(+3.0%) |
| Dec 1995 | -$3.30 M(-13.2%) | $100.00 K(-105.6%) | -$3.30 M(-26.7%) |
| Sep 1995 | - | -$1.80 M(-460.0%) | -$4.50 M(+28.6%) |
| Jun 1995 | - | $500.00 K(-123.8%) | -$3.50 M(-16.7%) |
| Mar 1995 | - | -$2.10 M(+90.9%) | -$4.20 M(+10.5%) |
| Dec 1994 | -$3.80 M(+111.1%) | -$1.10 M(+37.5%) | -$3.80 M(+2.7%) |
| Sep 1994 | - | -$800.00 K(+300.0%) | -$3.70 M(-17.8%) |
| Jun 1994 | - | -$200.00 K(-88.2%) | -$4.50 M(+15.4%) |
| Mar 1994 | - | -$1.70 M(+70.0%) | -$3.90 M(+116.7%) |
| Dec 1993 | -$1.80 M(-357.1%) | -$1.00 M(-37.5%) | -$1.80 M(+125.0%) |
| Sep 1993 | - | -$1.60 M(-500.0%) | -$800.00 K(-200.0%) |
| Jun 1993 | - | $400.00 K(0.0%) | $800.00 K(+100.0%) |
| Mar 1993 | - | $400.00 K | $400.00 K |
| Dec 1992 | $700.00 K(-153.8%) | - | - |
| Dec 1991 | -$1.30 M(-13.3%) | - | - |
| Dec 1990 | -$1.50 M | - | - |
FAQ
- What is Fresh Tracks Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Fresh Tracks Therapeutics?
- What is Fresh Tracks Therapeutics annual CFO year-on-year change?
- What is Fresh Tracks Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Fresh Tracks Therapeutics?
- What is Fresh Tracks Therapeutics quarterly CFO year-on-year change?
- What is Fresh Tracks Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Fresh Tracks Therapeutics?
- What is Fresh Tracks Therapeutics TTM CFO year-on-year change?
What is Fresh Tracks Therapeutics annual cash flow from operations?
The current annual CFO of FRTX is -$4.34 M
What is the all time high annual CFO for Fresh Tracks Therapeutics?
Fresh Tracks Therapeutics all-time high annual cash flow from operations is $700.00 K
What is Fresh Tracks Therapeutics annual CFO year-on-year change?
Over the past year, FRTX annual cash flow from operations has changed by +$14.99 M (+77.54%)
What is Fresh Tracks Therapeutics quarterly cash flow from operations?
The current quarterly CFO of FRTX is -$1.12 M
What is the all time high quarterly CFO for Fresh Tracks Therapeutics?
Fresh Tracks Therapeutics all-time high quarterly cash flow from operations is $15.94 M
What is Fresh Tracks Therapeutics quarterly CFO year-on-year change?
Over the past year, FRTX quarterly cash flow from operations has changed by $0.00 (0.00%)
What is Fresh Tracks Therapeutics TTM cash flow from operations?
The current TTM CFO of FRTX is -$4.34 M
What is the all time high TTM CFO for Fresh Tracks Therapeutics?
Fresh Tracks Therapeutics all-time high TTM cash flow from operations is $4.35 M
What is Fresh Tracks Therapeutics TTM CFO year-on-year change?
Over the past year, FRTX TTM cash flow from operations has changed by $0.00 (0.00%)